Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and Bionor Pharma ASA which

Read the full 399 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE